medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 Vaccination Prioritization Based on Cardiovascular Risk Factors and NumberNeeded-to-Vaccinate to Prevent Death

Darryl P. Leong1, MBBS, MPH, M.Biostat, PhD; Amitava Banerjee2, MA, MPH, DPhil; Salim
Yusuf1, MBBS, DPhil

1.

The Population Health Research Institute, McMaster University and Hamilton Health

Sciences and the Department of Health Research Methods, Evidence and Impact,

McMaster University

2.

Institute of Health Informatics, University College London

Corresponding author:
Darryl Leong

leongd@phri.ca

Authorsâ€™ declaration: The authors have no competing interests to declare.

ABSTRACT
The supply limitations of COVID-19 vaccines have led to the need to prioritize vaccine

distribution. Obesity, diabetes and hypertension have been associated with an increased

risk of severe COVID-19 infection. Approximately half as many individuals with a

cardiovascular risk factor need to be vaccinated against COVID-19 to prevent related death

as compared with individuals without a risk factor. Our analysis suggests that prioritizing

1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

adults with these cardiovascular risk factors for vaccination is likely to be an efficient way to

reduce population COVID-19 mortality.

INTRODUCTION
Vaccination is highly efficacious at preventing symptomatic COVID-19 infection(1-3). There

has consequently been unprecedented global demand for effective COVID-19 vaccines,

which has exceeded supply. Policymakers have implemented guidance for prioritising

vaccine distribution in their countries and jurisdictions. These policies are designed to

vaccinate those at highest risk of contracting COVID-19, being hospitalized or dying from the

condition. Current policy prioritizes the elderly, especially those institutionalized, with

evolving guidelines for other groups. The US Centers for Disease Control and Public Health

England suggest that individuals with certain underlying health conditions, which are

thought to be associated with increased COVID-19 morbidity and mortality, should be

prioritized for vaccination. As of February 23, 2021, Public Health Englandâ€™s guidance for

vaccination is that adults â‰¥65 years be prioritized highest; followed by adults <65 years with

2

diabetes, body-mass index â‰¥40kg/m , or other chronic disease; with healthy adults <65

years prioritized lowest. However, the public health benefits of such guidance have not

been demonstrated and in the absence of data on the population distribution of these

morbidities, the value of the strategies proposed cannot be quantified and are speculative.

Younger age and male sex are associated with an increased risk of acquiring COVID-

19, while in those who develop infection, older age and male sex are associated with a

higher risk of death. Cardiovascular risk factors are recognized risk factors for acquiring

COVID-19 (obesity and diabetes)(4) and have also been associated with a higher case-

2

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

fatality rate among those developing COVID-19 (obesity, diabetes and hypertension)(5, 6).

Therefore, adults in the general population with cardiovascular risk factors are likely to be at

higher risk of acquiring COVID-19 and also having a higher mortality should they get

infected. Consequently, the absolute reduction in COVID-19 risk from vaccinating these

individuals might be expected to be higher than non-obese individuals without diabetes or

hypertension. The objective of this analysis was to estimate the number of middle-aged and

older adults (age 40-80 years) needed-to-vaccinate to prevent a COVID-19 death in

populations with different clinical characteristics.

DATA SOURCES
The numbers of men and women stratified by age in Canada in 2020 were obtained from

estimates from the United Nations Department of Economic and Social Affairs(7). The

Canadian incidence rates of COVID-19 for the week of 31 January to 6 February, 2021, were

obtained from the Government of Canadaâ€™s website on COVID-19 epidemiological and

economic research data(8). We estimated the age-stratified and overall prevalence rates of

obesity, diabetes and hypertension using data from the Prospective Urban Rural

Epidemiology (PURE) study â€“ a large, prospective cohort study including 10,462 adults from

2

British Columbia, Ontario and Quebec. Obesity was defined as a body-mass index â‰¥30kg/m .

Diabetes included self-reported diabetes, use of blood glucose-lowering medications or a

fasting blood glucose level â‰¥7mmol/L. Hypertension included self-reported hypertension,

use of a blood pressure-lowering medication or blood pressure â‰¥140/90mmHg(9). We

observed a relative risk for COVID-19 infection among obese individuals (as compared with

2

those with a body-mass index 20 to <30kg/m ) of 1.53; a relative risk for COVID-19 infection

among adults with diabetes of 1.50; and a relative risk for COVID-19 infection among adults

3

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

with hypertension of 1.17 based on our analysis of 10,090 individuals from the PURE data

(unpublished). We used Public Health Ontarioâ€™s estimates of the COVID-19 case-fatality

ratio, which included data up to May, 2020(10). The effects of obesity on COVID-19 case-

2

fatality rates were estimated using data from a systematic review in which BMI â‰¥30kg/m

was associated with an odds ratio for death of 1.67 (95% CI 1.43-1.96)(11). Based on

another systematic review of the effects of co-morbidities on COVID-19 outcomes, we

assumed that those with diabetes and COVID-19 had a relative risk of death of 1.94 and that

those with hypertension and COVID-19 had a relative risk of death of 2.10 as compared with

infected individuals without diabetes or hypertension respectively(5). We estimated the

protective effect of vaccination by pooling (using random effects models) the estimates

from three randomised trials evaluating the Pfizer, Moderna and Oxford-Astra Zeneca

COVID-19 vaccines respectively(1-3).

We estimated the number-needed-to-vaccinate in each stratum of the Canadian

population as



à¬µ
à®ºà¯‹à¯‹

where the absolute risk reduction,

 
  19      
  19     

.

FINDINGS
In Canada, in 2020, there were 2,414,000 men aged 40-50 years; 2,597,000 men aged 50-60

years; 2,322,000 men aged 60-70 years; and 1,435,000 men aged 70-80 years. The

respective numbers of women in these age categories were 2,433,000; 2,585,000;

2,390,000; and 1,583,000. In Canada, the incidence rate of COVID-19 per 100,000 people

4

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

from 31 January to 6 February, 2021, was 85.2 among men aged 40-50 years; 72.7 among

men aged 50-60 years; 53.1 among men aged 60-70 years; and 40.3 among men aged 70-80

years. Respective rates among women were 84.5; 71.3; 44.4; and 39.2. In the PURE study,

rates of obesity, diabetes and hypertension among Canadian participants (above 35 years of

age) were respectively 26%, 9% and 38%. Rates of these risk factors stratified by age and sex

are presented in the Table. The pooled effect of COVID-19 vaccination on the risk of

acquiring COVID-19 (Figure 1) was a relative risk (95% CI) of 0.10 (0.03-0.34). Among those

who are infected with COVID-19, the case-fatality ratio (i.e. the proportion of identified

cases that succumb to the infection adjusted for censoring bias) according to Public Health

Ontario data is 0.67% for those aged 40-50 years; 2.03% for those aged 50-60 years; 6.52%

for those aged 60-70 years; and 20.89% for those aged 70-80 years. Using these data, we

estimated the numbers of individuals 1) in each age, sex and body-mass index stratum; 2)

among those with and without diabetes; and 3) among those with and without

hypertension who would develop and die from COVID-19 in the absence of vaccination

versus the numbers expected to develop and die from COVID-19 following vaccination.

Based on these data, the estimated numbers-needed-to vaccinate to prevent one COVID-19

death in Canadian adults overall is 33,595 and in men aged 70-80 years is 8722 and in

women aged 70-80 years is 9060. The estimated numbers-needed-to vaccinate to prevent

one COVID-19 death in different subgroups of the adult population are presented in the

Figure 2.

DISCUSSION
The major finding from this analysis of Canadian data on middle-aged and older adults is

that the number-needed-to-vaccinate to prevent COVID-19 death among those with

5

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

cardiovascular risk factors (obesity, diabetes or hypertension) is approximately half the

number-needed-to-vaccinate among adults without these cardiovascular risk factors.

Consequently, the number-needed-to-vaccinate of obese, diabetic and hypertensive adults

in any age group is similar to the number-needed-to-vaccinate of non-obese, non-diabetic

and normotensive adults 10 years older.

In most regions within Canada, COVID-19 vaccination is offered to the elderly first

(along with long-term care residents and frontline healthcare workers), followed by

members of the public in cohorts of successively decreasing age. Our analysis supports this

approach by demonstrating that vaccinating the elderly first is a highly efficient way of

preventing COVID-19 deaths. Once elderly individuals have been vaccinated, there remains

uncertainty as to how to prioritize vaccination of the remaining population. It has been

recognized that cardiovascular risk factors including obesity, diabetes and hypertension are

risk factors for both the acquisition of COVID-19 infection as well as for a fatal outcome in

the event of COVID-19 infection. Our analysis, which has been conducted using

contemporary data to inform the prevalence of these cardiovascular risk factors in the

Canadian population, suggests that preferentially vaccinating individuals with one or more

cardiovascular risk factors may be an efficient way to prevent COVID-19 mortality.

This analysis has several limitations. We assumed that COVID-19 vaccines are equally

effective among individuals with cardiovascular risk factors as among those without

cardiovascular risk factors. While there was no evidence from the randomized, controlled

trials of COVID-19 vaccinations to indicate that the efficacy of these vaccines varies

according to the recipientâ€™s age, sex or cardiovascular risk factors, data that have yet to be

peer-reviewed suggest that among 248 healthcare workers receiving the BNT 162b2

vaccine, the humoral immune response was larger among those with a â€œnormalâ€ body-mass

6

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

index as compared with a higher body-mass index(12). Also, while we demonstrate a

reduction in the number-needed-to-vaccinate to reduce mortality if those with

cardiovascular risk factors are vaccinated earlier, we have not estimated the number of

quality-adjusted life-years gained by such a strategy. If individuals without cardiovascular

risk factors gain more quality-adjusted life-years through COVID-19 vaccination, this may

attenuate the apparent advantages of preferentially vaccinating those with cardiovascular

risk factors earlier. We have not evaluated the potential impact of preferentially vaccinating

adults with chronic diseases other than obesity, diabetes and hypertension because there

were limited numbers of these diseases in the PURE data. Public Health England guidance

includes diseases such as dementia, kidney disease and recent cancer as conditions

warranting earlier vaccination, based in part on data from the UK National Health Service

demonstrating individuals with these diseases to be at higher risk of COVID-19 death(13,

14). Lastly, our analysis is based on the Canadian adult population distribution and

characteristics. These findings may not be generalizable to populations with substantially

different distributions of cardiovascular risk factors, although the general principles are

likely to hold.

BRIEF SUMMARY
â€¢

Approximately half as many individuals with a cardiovascular risk factor need to be

vaccinated against COVID-19 to prevent related death as compared with individuals

without a risk factor.

â€¢

2

Adults with body-mass index â‰¥30kg/m , diabetes or hypertension should be of a

similar priority for COVID-19 vaccination to adults 10 years older with a body-mass

2

index 20 to <30kg/m , no diabetes and no hypertension.

7

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES
1.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety

of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.

2.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and

Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.

3.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and

efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis

of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet.

2021;397(10269):99-111.

4.

Ho FK, Celis-Morales CA, Gray SR, Katikireddi SV, Niedzwiedz CL, Hastie C, et al.

Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for

influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open.

2020;10(11):e040402.

5.

Ng WH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB, et al.

Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis. mBio.

2021;12(1).

6.

Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk

factors on fatal outcomes in patients with COVID-19 according to age: a systematic review

and meta-analysis. Heart. 2021;107(5):373-80.

7.

United Nations, Department of Economic and Social Affairs

[Available from:

https://population.un.org/wpp/Download/Standard/Population/.

8.

Government of Canada COVID-19 epidemiological and economic research data

[Available from: https://www.canada.ca/content/dam/phac-

8

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

aspc/documents/services/diseases/2019-novel-coronavirus-infection/surv-covid19-weekly-

epi-update-20210212-eng.pdf.

9.

Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk

factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income,

middle-income, and low-income countries (PURE): a prospective cohort study. Lancet.

2020;395(10226):795-808.

10.

Public Health Ontario COVID-19 Case Fatality, Case Identification, and Attack Rates in

Ontario

[Available from: https://www.publichealthontario.ca/-

/media/documents/ncov/epi/2020/06/covid19-epi-case-identification-age-only-

template.pdf?la=en.

11.

Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, et al. Obesity in patients with

COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113:154378.

12.

Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, et al. OBESITY MAY

HAMPER SARS-CoV-2 VACCINE IMMUNOGENICITY. medRxiv. 2021:2021.02.24.21251664.

13.

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors

associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6.

14.

Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al.

Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from

coronavirus 19 in adults: national derivation and validation cohort study. BMJ.

2020;371:m3731.

Table. Prevalence rates of obesity, diabetes and hypertension among 11,000 Canadian
participants aged 35 to 70 years in the Prospective Urban Rural Epidemiology (PURE)
study.

9

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Group

Obesity

Diabetes

Hypertension

Men

23%

7%

23%

Women

20%

4%

10%

Men

30%

10%

30%

Women

28%

7%

28%

Men

29%

18%

29%

Women

29%

10%

29%

Men

33%

7%

33%

Women

32%

14%

32%

40-50 years

50-60 years

60-70 years

70-80 years

10

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1. Random effects meta-analysis of COVID-19 vaccines versus control for the
prevention of COVID-19 infection.

11

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. Estimated numbers-needed-to-vaccinate (NNV) to prevent a COVID-19 death.
Estimates are stratified by age 40-50 years versus 50-60 years versus 60-70 years.

12

medRxiv preprint doi: https://doi.org/10.1101/2021.03.24.21254227; this version posted March 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

13

